We strongly suggest that p16 IHC testing should be advised in the overall HNSCC population with additional confirmatory molecular testing such as PCR or ISH to be recommended for high-risk HPV in non-OPSCC subgroups. Here, CDKN2A is linked to head and neck squamous cell carcinoma.